Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients With Platinum Sensitive Relapsed Ovarian Cancer Who Are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer With Germline BRCA1/2 Mutation

NCT04330040 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04330040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04330040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients With Platinum Sensitive Relapsed Ovarian Cancer Who Are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer With Germline BRCA1/2 Mutation
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
May 25, 2020
Completion date
September 30, 2022
Enrollment
202 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, ovarian cancer